1. positive diagnostic test for sars-cov-2 infection ≤72 hours prior to randomization 2. subject-reported clinical history of covid-19 as determined by investigator 3. subject-reported history of prior positive diagnostic test for sars-cov-2 infection 4. active respiratory or non-respiratory symptoms suggestive or consistent with covid-19 5. medically attended acute illness, systemic antibiotics use, or hospitalization (ie, \>24 hours) for any reason within 30 days prior to screening 6. acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease \[copd\], asthma exacerbations) in the past 6 months prior to screening 7. received investigational or approved sars-cov-2 vaccine 8. received investigational or approved passive antibodies for sars-cov-2 infection prophylaxis as defined in the protocol 9. use of remdesivir, intravenous immunoglobulin (ivig), or other anti-sars viral agents within 2 months prior to screening note: other protocol-defined inclusion/ exclusion criteria apply

1. positive diagnostic test for sars-cov-2 infection ≤72 hours prior to randomization 2. subject-reported clinical history of covid-19 as determined by investigator 3. subject-reported history of prior positive diagnostic test for sars-cov-2 infection 4. active respiratory or non-respiratory symptoms suggestive or consistent with covid-19 5. medically attended acute illness, systemic antibiotics use, or hospitalization (ie, \>24 hours) for any reason within 30 days prior to screening 6. acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease \[copd\], asthma exacerbations) in the past 6 months prior to screening 7. received investigational or approved sars-cov-2 vaccine 8. received investigational or approved passive antibodies for sars-cov-2 infection prophylaxis as defined in the protocol 9. use of remdesivir, intravenous immunoglobulin (ivig), or other anti-sars viral agents within 2 months prior to screening note: other protocol-defined inclusion/ exclusion criteria apply

positive diagnostic test for sars-cov-2 infection ≤72 hours prior to randomization subject-reported clinical history of covid-19 as determined by investigator subject-reported history of prior positive diagnostic test for sars-cov-2 infection active respiratory or non-respiratory symptoms suggestive or consistent with covid-19 medically attended acute illness, systemic antibiotics use, or hospitalization (ie, >24 hours) for any reason within 30 days prior to screening acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease [copd], asthma exacerbations) in the past 6 months prior to screening received investigational or approved sars-cov-2 vaccine received investigational or approved passive antibodies for sars-cov-2 infection prophylaxis as defined in the protocol use of remdesivir, intravenous immunoglobulin (ivig), or other anti-sars viral agents within 2 months prior to screening note: other protocol-defined inclusion/ exclusion criteria apply

positive diagnostic test for sars-cov-2 infection ≤72 hours prior to randomization subject-reported clinical history of covid-19 as determined by investigator subject-reported history of prior positive diagnostic test for sars-cov-2 infection active respiratory or non-respiratory symptoms suggestive or consistent with covid-19 medically attended acute illness, systemic antibiotics use, or hospitalization (ie, >24 hours) for any reason within 30 days prior to screening acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease [copd], asthma exacerbations) in the past 6 months prior to screening received investigational or approved sars-cov-2 vaccine received investigational or approved passive antibodies for sars-cov-2 infection prophylaxis as defined in the protocol use of remdesivir, intravenous immunoglobulin (ivig), or other anti-sars viral agents within 2 months prior to screening note: other protocol-defined inclusion/ exclusion criteria apply

1. positive diagnostic test for sars-cov-2 infection ≤72 hours prior to randomization 2. subject-reported clinical history of covid-19 as determined by investigator 3. subject-reported history of prior positive diagnostic test for sars-cov-2 infection 4. active respiratory or non-respiratory symptoms suggestive or consistent with covid-19 5. medically attended acute illness, systemic antibiotics use, or hospitalization (ie, >24 hours) for any reason within 30 days prior to screening 6. acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease [copd], asthma exacerbations) in the past 6 months prior to screening 7. received investigational or approved sars-cov-2 vaccine 8. received investigational or approved passive antibodies for sars-cov-2 infection prophylaxis as defined in the protocol 9. use of remdesivir, intravenous immunoglobulin (ivig), or other anti-sars viral agents within 2 months prior to screening note: other protocol-defined inclusion/ exclusion criteria apply

1. positive diagnostic test for sars-cov-2 infection ≤72 hours prior to randomization 2. subject-reported clinical history of covid-19 as determined by investigator 3. subject-reported history of prior positive diagnostic test for sars-cov-2 infection 4. active respiratory or non-respiratory symptoms suggestive or consistent with covid-19 5. medically attended acute illness, systemic antibiotics use, or hospitalization (ie, >24 hours) for any reason within 30 days prior to screening 6. acute exacerbation of a chronic pulmonary condition (eg, chronic obstructive pulmonary disease [copd], asthma exacerbations) in the past 6 months prior to screening 7. received investigational or approved sars-cov-2 vaccine 8. received investigational or approved passive antibodies for sars-cov-2 infection prophylaxis as defined in the protocol 9. use of remdesivir, intravenous immunoglobulin (ivig), or other anti-sars viral agents within 2 months prior to screening note: other protocol-defined inclusion/ exclusion criteria apply